{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=42&state=Virginia", "query": { "state": "Virginia", "city": "Fairfax", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 2554, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=43&state=Virginia&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=41&state=Virginia&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T20:11:48.777Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04799054", "title": "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Head and Neck Squamous Cell Carcinoma HNSCC", "HPV-associated Cancers", "Neoadjuvant Melanoma", "Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)" ], "interventions": [ { "name": "TransCon TLR7/8 Agonist", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascendis Pharma Oncology Division A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2021-03-18", "completion_date": "2025-12-02", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799054" }, { "nct_id": "NCT01871805", "title": "A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2013-09-30", "completion_date": "2017-08-31", "has_results": true, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Irvine, California • La Jolla, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871805" }, { "nct_id": "NCT01189864", "title": "Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Keratoconus", "Ectasia", "Degeneration" ], "interventions": [ { "name": "Ciprofloxicin or Vigamox or other.", "type": "DRUG" }, { "name": "Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)", "type": "DRUG" }, { "name": "Steroid (FML, Pred Forte, Flarex, etc.)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cxlusa", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3493, "start_date": "2010-02-01", "completion_date": "2017-02-03", "has_results": false, "last_update_posted_date": "2018-10-12", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189864" }, { "nct_id": "NCT00490321", "title": "VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "End-stage Heart Failure", "Cardiomyopathies" ], "interventions": [ { "name": "VentrAssistTM Left Ventricular Assist Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ventracor", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2007-06", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2009-09-09", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Gainesville, Florida + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490321" }, { "nct_id": "NCT00110799", "title": "SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic", "Hepatitis C", "Thrombocytopenia" ], "interventions": [ { "name": "SB497115", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2005-04", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2012-06-04", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 9, "location_summary": "Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110799" }, { "nct_id": "NCT02414165", "title": "The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Toca 511", "type": "BIOLOGICAL" }, { "name": "Toca FC", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 403, "start_date": "2015-11-30", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414165" }, { "nct_id": "NCT03301311", "title": "Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Diseases", "Crohn Disease", "Ulcerative Colitis", "Indeterminate Colitis" ], "interventions": [ { "name": "Specific Carbohydrate Diet (SCD)", "type": "OTHER" }, { "name": "Modified Specific Carbohydrate Diet (MSCD)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "7 Years to 18 Years" }, "enrollment_count": 54, "start_date": "2018-04-10", "completion_date": "2020-09-08", "has_results": false, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 20, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Oakland, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03301311" }, { "nct_id": "NCT00576732", "title": "A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Autistic Disorder", "Autism" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Risperidone high dose", "type": "DRUG" }, { "name": "Risperidone low dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 96, "start_date": "2007-12", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 20, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Sacramento, California + 17 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00576732" }, { "nct_id": "NCT02675465", "title": "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pompe Disease" ], "interventions": [ { "name": "ATB200", "type": "DRUG" }, { "name": "AT2221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amicus Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2016-04", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Orange, California • Gainesville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02675465" }, { "nct_id": "NCT04757636", "title": "OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "2.0 mg OPT-302", "type": "BIOLOGICAL" }, { "name": "2.0 aflibercept", "type": "BIOLOGICAL" }, { "name": "Sham", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Opthea Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 998, "start_date": "2021-03-12", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-27T20:11:48.777Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04757636" } ] }